Analysts Offer Insights on Healthcare Companies: Neos Therapeutics (NASDAQ: NEOS), AveXis Inc (NASDAQ: AVXS) and Pfizer (NYSE: PFE)

By Jason Carr

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Neos Therapeutics (NASDAQ: NEOS), AveXis Inc (NASDAQ: AVXS) and Pfizer (NYSE: PFE).

Neos Therapeutics (NASDAQ: NEOS)

BMO Capital analyst Gary Nachman reiterated a Buy rating on Neos Therapeutics (NASDAQ: NEOS) yesterday and set a price target of $15. The company’s shares opened today at $6.60, close to its 52-week low of $5.30.

According to TipRanks.com, Nachman is a 4-star analyst with an average return of 8.9% and a 65.2% success rate. Nachman covers the Healthcare sector, focusing on stocks such as Amphastar Pharmaceuticals, Sucampo Pharmaceuticals, and Pacira Pharmaceuticals.

Currently, the analyst consensus on Neos Therapeutics is Moderate Buy and the average price target is $15, representing a 127.3% upside.

In a report released today, UBS also maintained a Buy rating on the stock with a $12 price target.
AveXis Inc (NASDAQ: AVXS)

BMO Capital analyst Ian Somaiya reiterated a Buy rating on AveXis Inc (NASDAQ: AVXS) yesterday. The company’s shares opened today at $67.62.

According to TipRanks.com, Somaiya is a 5-star analyst with an average return of 13.7% and a 55.5% success rate. Somaiya covers the Healthcare sector, focusing on stocks such as Aeglea Biotherapeutics Inc, Corcept Therapeutics Inc., and Protagonist Therapeutics.

Currently, the analyst consensus on AveXis Inc is Strong Buy and the average price target is $66.83, representing a -1.2% downside.

In a report issued on November 1, Jefferies also reiterated a Buy rating on the stock with a $71 price target.
Pfizer (NYSE: PFE)

BMO Capital analyst Alex Arfaei reiterated a Hold rating on Pfizer (NYSE: PFE) yesterday and set a price target of $33. The company’s shares opened today at $33.22.

According to TipRanks.com, Arfaei is a 4-star analyst with an average return of 4.2% and a 61.0% success rate. Arfaei covers the Healthcare sector, focusing on stocks such as Kindred Biosciences, Merck & Company, and Eli Lilly & Co.

Currently, the analyst consensus on Pfizer is Moderate Buy and the average price target is $36.67, representing a 10.4% upside.

In a report issued on November 2, Argus Research also downgraded the stock to Hold.